[go: up one dir, main page]

AR039783A1 - Metodos mejorados de purificacion viral - Google Patents

Metodos mejorados de purificacion viral

Info

Publication number
AR039783A1
AR039783A1 ARP030101504A ARP030101504A AR039783A1 AR 039783 A1 AR039783 A1 AR 039783A1 AR P030101504 A ARP030101504 A AR P030101504A AR P030101504 A ARP030101504 A AR P030101504A AR 039783 A1 AR039783 A1 AR 039783A1
Authority
AR
Argentina
Prior art keywords
virus
viruses
cell culture
improved methods
detergent
Prior art date
Application number
ARP030101504A
Other languages
English (en)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29406789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR039783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR039783A1 publication Critical patent/AR039783A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se refiere a un método mejorado de purificación de virus, en particular reovirus. Se pueden extraer virus infecciosos de un cultivo celular con un detergente para producir títulos virales más altos y el virus puede ser purificado luego mediante pasos simples tal como filtración y cromatografía en columna. También se proveen virus y composiciones que comprenden virus preparadas de acuerdo con la presente. Reivindicación 1: Un método para producir virus a partir de un cultivo de células, caracterizado porque comprende los pasos de: a) proveer un cultivo de células que ha sido infectado con el virus; b) extraer el virus de las células por adición de un detergente al cultivo e incubarlo por un período de tiempo para obtener un lisado celular; c) eliminar los desechos celulares; y d) recolectar el virus.
ARP030101504A 2002-04-30 2003-04-29 Metodos mejorados de purificacion viral AR039783A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37727302P 2002-04-30 2002-04-30
US44317603P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
AR039783A1 true AR039783A1 (es) 2005-03-02

Family

ID=29406789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101504A AR039783A1 (es) 2002-04-30 2003-04-29 Metodos mejorados de purificacion viral

Country Status (16)

Country Link
US (3) US7223585B2 (es)
EP (1) EP1501921B2 (es)
JP (1) JP2005523722A (es)
AR (1) AR039783A1 (es)
AT (1) ATE427990T1 (es)
AU (1) AU2003229159B2 (es)
BR (1) BR0309659A (es)
CA (1) CA2482512C (es)
DE (1) DE60327069D1 (es)
DK (1) DK1501921T4 (es)
ES (1) ES2323454T5 (es)
IL (1) IL164551A (es)
MX (1) MXPA04010603A (es)
NZ (1) NZ535944A (es)
TW (1) TWI317378B (es)
WO (1) WO2003093463A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501921B2 (en) 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Improved viral purification methods
MXPA05005306A (es) 2003-06-20 2005-10-26 Microbix Biosystems Inc Mejoramientos en la produccion de virus.
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US8373381B2 (en) 2005-04-22 2013-02-12 GM Global Technology Operations LLC DC/DC-less coupling of matched batteries to fuel cells
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
BRPI0710820A2 (pt) * 2006-04-20 2011-08-23 Wyeth Corp processo para a purificação do vìrus da estomatite vesicular (vsv) do fluido de cultura celular de uma cultura de células de mamìferos infectada com vsv; vsv purificado de acordo com o processo; composição farmacêutica; e composição imunogênica
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
CA2738024A1 (en) * 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
MX350932B (es) 2010-12-02 2017-09-26 Oncolytics Biotech Inc Formulaciones virales liquidas.
US20120273424A1 (en) * 2011-04-29 2012-11-01 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
WO2014145578A1 (en) * 2013-03-15 2014-09-18 The Children's Hospital Of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
US20160329387A1 (en) * 2014-01-14 2016-11-10 Koninklijke Philips N.V. Organic light emitting diode
WO2016130569A1 (en) * 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR102652994B1 (ko) 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
KR102850887B1 (ko) 2017-08-03 2025-08-28 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3762500A1 (en) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
AU2019299861A1 (en) 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
MX2021000810A (es) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
JP2022522995A (ja) 2019-01-18 2022-04-21 ボイジャー セラピューティクス インコーポレイテッド Ａａｖ粒子を生成するための方法及びシステム
TW202106879A (zh) 2019-04-29 2021-02-16 美商航海家醫療公司 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20220298547A1 (en) * 2021-03-19 2022-09-22 Pathogendx, Inc. Multiplex Viral Pathogen Analysis and Uses Thereof
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4642902A1 (en) * 2023-04-21 2025-11-05 National Research Council of Canada Improvement in viral extraction from cell culture

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
JPS6344532A (ja) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk 豚のレオウイルス感染症ワクチン
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
AU693203B2 (en) 1994-05-16 1998-06-25 Merck Sharp & Dohme Corp. Papillomavirus vaccines
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JPH11511326A (ja) * 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
WO1998026048A1 (en) 1996-12-13 1998-06-18 Schering Corporation Methods for purifying viruses
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
JP4087712B2 (ja) * 2001-03-16 2008-05-21 オンコリティクス バイオテック， インコーポレイティッド 細胞培養物からウイルスを抽出する方法
EP1501921B2 (en) 2002-04-30 2012-07-25 Oncolytics Biotech Inc. Improved viral purification methods
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
ES2323454T5 (es) 2012-11-14
CA2482512A1 (en) 2003-11-13
US8685734B2 (en) 2014-04-01
TWI317378B (en) 2009-11-21
DK1501921T4 (da) 2012-10-08
EP1501921A1 (en) 2005-02-02
EP1501921B2 (en) 2012-07-25
WO2003093463A1 (en) 2003-11-13
US7223585B2 (en) 2007-05-29
DK1501921T3 (da) 2009-06-22
MXPA04010603A (es) 2004-12-13
TW200401829A (en) 2004-02-01
EP1501921B1 (en) 2009-04-08
US20140178969A1 (en) 2014-06-26
IL164551A0 (en) 2005-12-18
BR0309659A (pt) 2005-02-22
US20040005693A1 (en) 2004-01-08
AU2003229159B2 (en) 2008-02-21
HK1070670A1 (en) 2005-06-24
DE60327069D1 (de) 2009-05-20
ATE427990T1 (de) 2009-04-15
CA2482512C (en) 2011-09-20
US20070269856A1 (en) 2007-11-22
US10167452B2 (en) 2019-01-01
IL164551A (en) 2010-05-17
AU2003229159A1 (en) 2003-11-17
NZ535944A (en) 2007-11-30
JP2005523722A (ja) 2005-08-11
ES2323454T3 (es) 2009-07-16

Similar Documents

Publication Publication Date Title
AR039783A1 (es) Metodos mejorados de purificacion viral
BRPI0516221A (pt) método de produção de vìrus de uma cultura de células, composição, e, método de produção de reovìrus infeccioso
EA200601231A1 (ru) Дефинитивная энтодерма
AR123811A2 (es) Composiciones de células madre mesenquimáticas purificadas y métodos relacionados
CO2022010432A2 (es) Método basado en tecnología leaper para el tratamiento de mucopolisacaridosis ih y composición
DK1526172T3 (da) Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira
CL2011001906A1 (es) Compuestos derivados de ribosidos de tieno[3,4-d]pirimidin-7-ilo, y fosfatos de ribosidos; compuestos intermediarios; metodos de preparacion; metodo de tratamiento; composicion farmaceutica; y su uso para tratar una infeccion viral causada por un virus hepatitis c o un virus flaviridae.
EA200200604A1 (ru) Производство вакцин
PE20091218A1 (es) Anticuerpo anti-glipicano 3 con cinetica en plasma mejorada
HN2006041184A (es) Metodos y estuches para dosificar nucleosidos antivirales beta-d-2 3- didehydro-2 , 3-dideoxy 5- fluorocytidina
DK1194580T3 (da) In vitro-rekonstruktion af segmenterede negativ-strengede RNA-virus
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
BR0313559A (pt) Método para o cultivo de células primárias e para a amplificação de vìrus sob condições isentas de soro
EA201291225A1 (ru) Улучшенные способы получения сквалена
EA201270173A1 (ru) Получение полиовируса с высокими титрами для получения вакцины
AR078253A1 (es) Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
AR079710A1 (es) Proceso para el cultivo de celulas adherentes
BR0207527A (pt) Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
MX387420B (es) Producción de virus en cultivos celulares.
ES2530694T3 (es) Factor de permisividad celular para virus, y usos del mismo
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
AR069885A1 (es) Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional
AR069884A1 (es) Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa
DK1889834T3 (da) Ny organisk forbindelse og fremgangsmåde til at fremstille radioaktiv halogenmærket organisk forbindelse ved anvendelse af samme
WO2003049767A3 (en) Method of large scale production of hepatitis a virus

Legal Events

Date Code Title Description
FB Suspension of granting procedure